, led by Kevin Kotler
, in a filing with the Securities and Exchange Commission, reported initiating a position in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)
. The fund currently owns 896,100 shares, which is equivalent to 5.55% of the common stock of the company.
Eleven Biotherapeutics, Inc. (NASDAQ:
EBIO) is a Massachusetts based company, focused on discovering and developing protein therapeutics to treat ocular diseases. The stock of the company began trading on the NASDAQ Global Market a couple of weeks ago. The company raised $50.0 million in an initial public offering of 5.00 million shares of its common stock at a price of $10.00 per share.
At the end of the fourth quarter of 2013, total value of the equity portfolio of Broadfin Capital was $1.45 billion. Kevin Kotler’s Broadfin Capital had the largest investment in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
, the position amassing 391,232 shares, worth $702.65 million. The next big holding in its equity portfolio is the specialty pharmaceutical company, Depomed Inc (NASDAQ:DEPO)
, in which the fund reported 4.74 million shares, with a value of $50.2 million. Another significant investment of the fund is in Lannett Company, Inc. (NASDAQ:LCI)
with a reported stake of 1.34 million shares, worth $44.35 million.
Early this year, the fund revealed a new stake in Retrophin Inc (NASDAQ: RTRX)
Capital now owns 1.61 million shares in this biotechnology company
, which is equivalent to 6.93% of the common stock of Retrophin Inc (NASADQ:
Late last year, Kevin Kotler’s Broadfin Capital upped its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to 4.5 million shares from around 3.6 million shares held earlier
. Around the same period, the fund also increased its position in Derma Sciences Inc (NASDAQ:DSCI)
to 871,600 shares from 771, 600 shares held earlier
Edward Gilhuly and Sageview Capital’s New Stock Moves
Lance Helfert and Paul Orfalea’s Top Holdings and Latest Sales
New Picks of Steve Cohen’s SAC Capital Advisors